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OBJECTIVES: Acute ST-elevation myocardial infarction is associated with ventricular dysfunction due to
ischemia-induced progressive myocardial damage. The decrease in ventricular compliance causes left atrial
dilatation and stretching of the atrial myocardium, which are the main stimuli for the secretion of atrial
natriuretic peptide. The aim of this study was to evaluate left atrial dimensions and atrial natriuretic peptide
levels in patients early after their first acute ST-elevation myocardial infarction and assess the probable
interaction between coronary lesions and these measurements.
METHODS: A total of 110 patients with acute myocardial infarction and 50 controls were studied. Plasma atrial
natriuretic peptide was measured at admission. Left ventricular function, diameter, and volume index were
evaluated using transthoracic echocardiography. Gensini and vessel scores of the patients who underwent
coronary angiography were calculated.
RESULTS: Plasma atrial natriuretic peptide in the patients with myocardial infarction was increased compared
with that in controls (3.90¡3.75 vs. 1.35¡0.72 nmol/L, p,0.001). Although the left atrial diameter was
comparable in patients and controls, the left atrial volume index was increased in patients with acute
myocardial infarction (26.5¡7.1 vs. 21.3¡4.9 mL/m2, p,0.01). Multivariate regression analysis showed a strong
independent correlation between the left atrial volume index and the plasma atrial natriuretic peptide level
(b=0.23, p= 0.03).
CONCLUSIONS: The left atrial volume index and plasma atrial natriuretic peptide level were correlated in
patients with acute myocardial infarction.
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& INTRODUCTION
Coronary artery disease (CAD) is the leading cause of both
morbidity and mortality worldwide (1). It encompasses a wide
clinical spectrum ranging from silent ischemia to sudden death.
Within this spectrum, acute ST-segment elevation myocardial
infarction (STEMI) is the most significant form of the disease
with respect to its diagnosis, treatment, and prognosis. Various
degrees of left ventricular systolic and diastolic dysfunction
occur during STEMI (2). Several parameters are used for the
determination of left ventricular (LV) diastolic function, but
most of them are affected by a number of technical and
physiological factors, including heart rate, age, cardiac rhythm,
preload, afterload, and LV geometry (3).
The atria are cardiac structures that are often overlooked
during a routine echocardiographic examination (4). In
general, the measurement of left atrial antero-posterior
diameter (LAAPD) with M-mode echocardiography is
considered sufficient. Although this method is simple, its
accuracy in reflecting LA size is controversial due to the
asymmetric structure of the LA. Volume calculation
represents LA size more consistently than diameter or area
measurements. The LA volume indexed to body surface
area (LAVI) is the recommended method for LA size
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quantification (5). Increased LA volume is a strong predictor
of mortality after STEMI and provides superior prognostic
information compared with conventional LV systolic and
diastolic function measurements and clinical data (6).
The natriuretic peptides comprise several structurally
related molecules, such as atrial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP), which play important
roles in cardiovascular homeostasis (7). ANP is secreted
from atria as a response to increased intra-atrial pressure
and is eliminated from the circulation in minutes either
enzymatically or through the clearance receptor (8). The
biologically inactive N-terminal peptide of pro-atrial
natriuretic peptide (NT-proANP) is secreted into plasma
in equimolar amounts as ANP, but it has a higher plasma
concentration than ANP due to decreased degradation in
vivo, which makes it a more appropiate biomarker (9).
Plasma ANP is increased in STEMI due to LV load and
myocardial damage (10,11). In patients with STEMI, the
plasma ANP level helps predict the prognosis and identify
high-risk patients (12). Svanegaard et al. demonstrated that
the distension of the LA, rather than the dilatation of the LV,
is related to the concentration of ANP (13). To our
knowledge, no study has investigated the association
between LAVI and plasma ANP level during STEMI. The
purpose of this study was to evaluate LAVI and ANP in
patients with STEMI.
& MATERIALS AND METHODS
Patients
This prospective study enrolled 110 patients with a
STEMI diagnosis. A diagnosis of acute STEMI was made
based on the current criteria (14). Additionally, 50 age- and
gender-matched subjects with complaints of exercise angina
who underwent elective coronary angiography that
revealed normal coronary arteries were used as the control
group.
The following were exclusion criteria because of the
influence of each condition on echocardiographic variables
or the ANP level: a) patients admitted to a hospital more
than 12 hours after the onset of symptoms; b) patients who
presented with a heart rhythm other than sinus rhythm; c)
patients whose echogenicity was insufficient for transthor-
acic echocardiographic examination; d) patients with atrial
infarction (elevated PR segment at leads I, II, III, V5, and V6;
0.15-mV depression at precordial leads; or 0.12-mV depres-
sion at leads I, II, and III); e) patients with Killip class $III
heart failure or cardiogenic shock; f) patients with renal
failure (serum creatinine $1.5 mg/dL), chronic pulmonary
or hepatic disease, or cancer; g) patients with an acute
infection, severe trauma, surgical operation or burns within
the last month; h) patients with a history of prior MI,
percutaneous coronary intervention (PCI), or coronary
artery by-pass graft operation; i) and patients with
cardiomyopathy or moderate to severe valvular heart
disease. Only patients with Thrombolysis in Myocardial
Infarction grade 3 flow in the infarct-related artery (IRA)
after PCI and patients with $50% ST resolution at 90
minutes after fibrinolysis were included in the study to
eliminate the possible effects of inadequate reperfusion.
Age, gender, height, weight, waist and hip circumfer-
ences, and atherosclerotic risk factors were recorded for all
patients. Body mass index (BMI) and body surface area
(BSA) were calculated. Pulse and blood pressure were
measured at the time of presentation. All patients were
informed about the nature and purpose of the study, which
was approved by the local ethics committee.
Echocardiographic evaluation
All patients were evaluated by two-dimensional pulsed-
wave Doppler and pulsed-wave tissue Doppler echocardio-
graphy. The electrocardiogram-guided echocardiographic
examination conducted using a transthoracic approach was
performed by an experienced sonographer who was
blinded to the study, with the patient in the left lateral
decubitus position within 48 hours after admission, by
using Philips ATL HDI 5000 (Philips Medical Systems,
Advanced Technology Laboratories, Bothell, Washington,
USA) and Philips Envisor C HD (Philips Medical Systems,
Andover, MA, USA) echocardiography devices and 2–4-
MHz phase transducers. All measurements were obtained
as per the criteria recommended by the American
Echocardiography Society (5). The left atrial antero-poster-
ior diameter (LAAPD) and septal wall thickness were
obtained from standard parasternal long-axis images. Left
ventricular end-systolic (LVESD) and end-diastolic diameter
(LVEDD) and ejection fraction (EF) from apical four- and
two-chamber views were measured by using the modified
Simpson method (15). Transmitral flow samples were
obtained by pulsed-wave (PW) Doppler such that apical
four-chamber views were parallel to the blood flow with the
sample volume located at the level of the mitral leaflet tips.
From the recordings, peak early (E) and late (A) transmitral
filling velocities, isovolumic contraction time (IVCT), iso-
volumic relaxation time (IVRT), and ejection time (ET) were
measured, and the LV myocardial performance index (MPI)
was calculated.
The maximal LA volume was measured from the apical
four-chamber view by using the modified Simpson method
in end-systole before mitral valve opening. The LAVI was
obtained for all patients by dividing the LA volume by the
BSA. Additionally, early diastolic velocity (Em) was
measured using the tissue Doppler function of the same
devices, with the sample volume from the apical four-
chamber view located at the septal edge of the mitral
annulus. The average value of three consecutive heart beats
was obtained at the end of exhalation.
To assess the intra-observer variability, echocardio-
graphic measurements were repeated in ten subjects the
next day by the same investigator. To assess the inter-
observer variability, transthoracic echocardiography was
performed by a second observer on the same ten patients
after the first echocardiography. The intra- and inter-
observer variability of LA volume were 7.5¡6.1 and
9.3¡7.2 mL, respectively, indicating good agreement.
Coronary angiography
Coronary angiography was performed using a mono-
plane cine-angiography system (Philips Optimus 200 DCA
and Integris Allura 9 angiography devices; Philips Medical
Systems, Eindhoven, Netherlands). Selective coronary
angiography was performed at standard positions by the
Judkins technique and a right and left transfemoral
approach. Iopromide (Ultravist 370, Schering AG, Berlin,
Germany) was used as opaque material. Angiographies
were recorded at 25 frames/second by using 35-mm
cinefilm. The Gensini score and vessel score were used to
determine the severity and the extent of atherosclerotic
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CAD, respectively (16,17). For coronary artery scoring, one
point was assigned to each artery when there was 70% or
more stenosis in the three main coronary arteries and their
major side branches. One additional point was assigned
when there was 50% or greater stenosis in the left main
coronary artery (LMCA), with a maximum total score of 4.
The Gensini score was obtained by considering the severity
of lesions at certain segments of the LMCA, left anterior
descending artery (LAD), circumflex artery (Cx), and right
coronary artery (RCA). A total of 2, 4, 8, 16, 32, and 64 points
were assigned for each lesion with an obstruction level of 0–
24, 25–49, 50–74, 75–89, 90–99, and 100%, respectively. If the
RCA was the most obstructed artery, the lesion score for the
LMCA was multiplied by a constant multiplier of 5; the
lesion score for the proximal LAD and Cx was multiplied by
2.5; the score for a medial LAD lesion was multiplied by 1.5;
the scores for RCA, distal LAD, and distal Cx lesions were
multiplied by 1; the scores for the optus marginalis (OM1)
and diagonal (D1) side branches were multiplied by 1; and
the scores for other side branches were multiplied by 0.5.
The total Gensini score was obtained by adding the
resultant numbers. If the left system was dominant, the
scores of RCA proximal, medial, and distal segment lesions
were multiplied by a constant multiplier of 0.5. Ultimately,
the total Gensini score was obtained numerically, which
showed the severity of CAD. All coronary angiograms were
evaluated by two observers who were blinded to the study.
The inter- and intra-observer variability for repeated
evaluations of the angiograms of 20 randomly selected
patients was low (for the Gensini score: inter-observer
variability, 4.8¡2.9%; intra-observer variability, 4.1¡2.5%).
Laboratory investigations
Venous blood samples were collected from all patients at
the time of admission to the emergency department. Serum
glucose; creatinine; cardiac markers, such as the MB fraction
of creatine kinase (CK-MB) and troponin I; plasma
hemoglobin; platelet count; and white blood cell (WBC)
count were measured. Additionally, venous blood was
collected after 12 hours of fasting and used to analyze the
lipid profile within 24 hours. Blood samples required for
ANP measurements were collected in EDTA tubes (two
tubes, each containing 3 mL of blood) within 12 hours after
admission from the antecubital vein while the patient was in
the supine position. Plasma was obtained by the centrifuga-
tion of blood at 3,000 rpm for 10 minutes at 4¡2 C˚ by a
cooling centrifuge. Plasma samples (200 mL) were collected
in small Eppendorf tubes and stored at 280 C˚. Plasma NT-
proANP was measured using a commercially available
ELISA kit [Enzyme Immunoassay for the Quantitative
Determination of Human proANP (1–98) in EDTA Plasma,
Heparin Plasma, Urine or Cell Culture Supernatants; Cat.
No. BI-20892, Biomedica, Vienna, Austria].
Statistical analysis
Statistical analysis of the data was performed using SPSS
Version 13.0 software (SPSS Inc., Chicago, Illinois, USA).
Continuous variables are reported as the means¡ standard
deviations (SDs), and categorical variables are expressed as
percentages. The categorical and continuous variables were
compared between the two groups using the x2 test and
unpaired t-test, respectively. Correlation analysis was
performed to assess the relationships between the LAVI,
the ANP level, and other variables. For the correlation
analysis, Pearson’s correlation test was used to analyze data
that exhibited a parametric distribution, and Spearman’s
correlation test was used to evaluate associations between
data with a non-parametric distribution. A multivariate
linear regression analysis was performed to assess the
power of the relationships between the ANP level and
correlating variables. A step-by-step ‘‘backward’’ method
was used for the linear regression analysis. A chi-square test
was used to assess associations between categorical data.
The Student’s t test was performed for pairwise compar-
isons of the ANP level. A two-sided p-value ,0.05 was
considered statistically significant.
& RESULTS
Table 1 shows the baseline characteristics of the study
population. There were no statistically significant differ-
ences in age, gender, cigarette smoking, BMI, or waist
circumference between the groups. Biochemical data were
not significantly different between groups, with the excep-
tion that higher levels of cardiac markers and leukocytosis
were observed in patients with STEMI.
The majority of patients with STEMI enrolled in this study
were middle-aged males (85.5%, mean age 56.2¡10.4 years).
Most of the patients (n = 62, 56.4%) had an STEMI localized
at the anterior wall, and their IRA was the LAD.
Additionally, most of the patients (n = 90, 81.8%) had
primary PCI (mean 2.8¡2.2 hours; minimum 45 minutes,
maximum 6 hours), and 20 patients (18.2%) were given
fibrinolytic therapy with streptokinase (1,500,000 IU over 45
minutes by intravenous infusion) within the first three
hours (mean 2.4¡0.8 hours) (Table 2).
Echocardiographic measurements are shown in Table 3.
Conventional measurements revealed a normal LV size in
both groups and impaired LV systolic function in patients
with STEMI (LVEF in patients vs. controls: 49.4¡7.1% vs.
60.5¡5.2%, p,0.01). With regard to diastolic function, only
Table 1 - Demographic characteristics and laboratory
values of the study population. Data are the mean ¡
standard deviation.
Patients (n = 110) Control (n = 50) p-value
Age (years) 56.2¡10.4 54.4¡6.4 NS
Gender (male)(%) 94 (85.5%) 37 (74.0%) NS
BMI (kg/m2) 27.0¡4.4 28.3¡3.5 NS
Waist circumference (cm) 95.9¡11.7 97.1¡8.7 NS
Current smoker (%) 82 (74.5%) 36(72%) NS
Hypertension (%) 31 (28.3%) 17 (34%) NS
Diabetes mellitus (%) 19 (17.3%) 12 (24%) NS
HR (bpm) 72.5¡12.0 70.1¡9.6 NS
BP (systolic/diastolic)
(mmHg)
110¡20/70¡10 115¡20/75¡15 NS
Glucose (mg/dL) 154.0¡53.8 146.1¡45.8 NS
Creatinine (mg/dL) 0.9¡0.2 1.0¡0.4 NS
Hemoglobin (g/dL) 14.4¡1.6 13.6¡1.9 NS
Platelets (6103/mL) 231.6¡65.2 246.3¡59.2 NS
WBCs (6103/mL) 12.4¡3.9 8.4¡2.7 ,0.001
LDL cholesterol (mg/dL) 120.8¡39.4 119.7¡27.8 NS
HDL cholesterol (mg/dL) 36.7¡8.8 39.3¡10.5 NS
Triglycerides (mg/dL) 140.6¡44.8 136.3¡41.7 NS
Peak troponin I (ng/dL) 96.1¡63.5 0.3¡0.2 ,0.001
Peak CK-MB (ng/dL) 197.6¡18.5 3.0¡1.4 ,0.001
BMI: body mass index; HR: heart rate; BP: blood pressure; WBC: white
blood cell, LDL: low-density lipoprotein; HDL: high-density lipoprotein;
CK-MB: creatine kinase isoenzyme MB.
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E/Em increased in patients (8.7¡3.3 vs. 7.9¡2.8, p= 0.04).
Although LA diameters were comparable between patients
and controls, the LAVI was increased in patients with STEMI
(26.5¡7.1 vs. 21.3¡4.9 mL/m2, p,0.01). The LAVI was
correlated with LAAPD (p,0.05). Of the clinical features
investigated, only the presence of hypertension was asso-
ciated with LAVI (29.2 vs. 24.7 mL/m2, p= 0.02). There was
no association between the LAVI and angiographic indexes.
NT-proANP levels were significantly higher in patients
than controls (3.90¡3.75 vs. 1.35¡0.72 nmol/L, p,0.001).
The Student’s t test was used to assess the effect of patient
demographic characteristics on plasma NT-proANP levels.
NT-proANP levels were elevated in hypertensive patients
and diabetic patients (5.34 vs. 3.05 nmol/L, p= 0.01 and 5.38
vs. 3.29 nmol/L, p= 0.03, respectively). A correlation analy-
sis was performed to analyze the association between
patients’ NT-proANP levels with other variables, which
showed that the NT-proANP level was correlated with age,
diastolic blood pressure at the time of admission, peak
troponin I value, and Gensini score (Table 4). When the NT-
proANP level was examined with respect to the revascular-
ization method used, patients who underwent PCI were
found to have higher NT-proANP levels compared with
those who did not undergo PCI (4.21 vs. 1.87 nmol/L for
patients who underwent primary PCI vs. patients who
received fibrinolytic therapy; p= 0.03). The time until
revascularization was correlated with the NT-proANP level
in patients who underwent primary PCI (p= 0.02). No
associations were found between the NT-proANP level and
echocardiographic parameters used to determine LV sys-
tolic and diastolic dysfunction (p.0.05). The LAVI was the
only echocardiographic variable that correlated with the
NT-proANP level (r = 0.28, p= 0.01) (Figure 1). A linear
regression analysis using stepwise backward regression was
performed to show dependent and independent effects of
variables that were found to correlate with the ANP level.
All parameters showing a correlation (age, diastolic blood
pressure at the time of admission, peak troponin I level,
Gensini score, and LAVI) were included in the analysis.
Age, peak troponin I level, and LAVI were independently
associated with NT-proANP level (Table 5).
& DISCUSSION
In this study, we evaluated LAVI and plasma NT-
proANP in patients with STEMI. The level of ANP and
the amount of LA dilation are strong and independent
predictors of morbidity and mortality during STEMI (6,10).
Although the relationship between LV characteristics and
the NT-proANP level has been demonstrated previously,
this is the first study to identify associations between LAVI,
NT-proANP level, and clinical data, such as MI location,
IRA, and the severity and extent of CAD in STEMI. The
results of this study reveal that both the LAVI and NT-
proANP level are affected to similar degrees during STEMI
and seem compatible with each other.
The dimensions and functions of the atria, particularly the
LA, have clinical significance in many cardiovascular
Table 2 - Clinical and angiographic characteristics of the
patients with acute STEMI.
Variable Patients (n = 110)
MI location (anterior/other) (%) 56.4/43.6
IRA (LAD/Cx/RCA) (%) 56.4/6.4/37.2
Therapy (PCI/lytic) (%) 81.8/18.2
Pre-infarct angina (%) 70.9
Gensini score 104.0¡54.6
Vessel score 1.5¡0.7
STEMI: ST-segment elevation myocardial infarction; MI: myocardial
infarction; IRA: infarct-related artery; LAD: left anterior descending
coronary artery; Cx: left circumflex coronary artery; RCA: right coronary
artery; PCI: percutaneous coronary intervention.
Table 3 - Echocardiographic measurements of the study
population. Data are the mean ¡ standard deviation.
Patients (n = 110) Control (n = 50) p-value
LV size and systolic function
LVESD (cm) 3.2¡0.4 3.5¡0.7 NS
LVEDD (cm) 4.8¡0.4 4.7¡0.6 NS
IVS (cm) 0.9¡0.1 1.0¡0.2 NS
PW (cm) 0.9¡0.1 0.9¡0.1 NS
LVMI (gr/m2) 82.2¡24.2 83.9¡21.4 NS
LVEF (%) 49.4¡7.1 60.5¡5.2 ,0.001
Diastolic function
E (cm/s) 68.2¡17.1 73.7¡16.8 NS
A (cm/s) 69.7¡18.7 63.8¡15.1 NS
DT (ms) 154.8¡36.0 157.3¡38.9 NS
IVRT (ms) 91.9¡21.0 88.5¡12.3 NS
LV MPI 0.52¡0.10 0.49¡0.05 NS
LV Em (cm/s) 8.3¡2.1 8.9¡1.6 NS
LV E/Em ratio 8.7¡3.3 7.9¡2.8 0.04
Atrial measurements
LAAPD (cm) 3.6¡0.4 3.8¡1.2 NS
LAVI (mL/m2) 26.5¡7.1 21.3¡4.9 0.001
LVESD: left ventricle end-systolic diameter; LVEDD: left ventricle end-
diastolic diameter; IVS: interventricular septal thickness; PW: left
ventricular posterior wall thickness; LVMI: left ventricular mass index;
LVEF: left ventricular ejection fraction; LV: left ventricle; E: peak mitral
valve flow velocity during the early rapid filling phase; A: peak mitral
valve flow velocity during atrial contraction; DT: diastolic time; IVRT:
isovolumetric relaxation time; MPI: myocardial performance index; Em:
early diastolic velocity; LAAPD: left atrial antero-posterior diameter; LAVI:
left atrial volume index.
Table 4 - Correlations of NT-proANP with other variables
in patients with acute STEMI.
Variable Correlation coefficient (r) p-value
Age (years) 0.235 0.02
Peak troponin I level (ng/dL) 0.273 0.01
Gensini score 0.258 0.01
IVS thickness (cm) 0.239 0.01
LAVI (mL/m2) 0.283 0.01
NT-proANP: N-terminal pro-atrial natriuretic peptide; STEMI: ST-segment
elevation myocardial infarction; IVS: interventricular septal thickness;
LAVI: left atrial volume index.
Table 5 - Variables associated with NT-proANP levels in
patients with STEMI (Nagelkerke R2 = 0.247 for the
multivariate regression model).
Variable b p-value
Age (years) 0.289 0.01
Peak troponin I levels (ng/dL) 0.364 0.01
LAVI (ml/m2) 0.232 0.03
NT-proANP: N-terminal peptide of proatrial natriuretic peptide, STEMI:
Acute ST segment-elevation myocardial infarction, LAVI: left atrial volume
index.
LAVI and NT-proANP in AMI
Bacaksiz A et al.
CLINICS 2013;68(7):997-1003
1000
conditions (6,18–20). The enlargement of the LA has been
associated with an increased incidence of atrial fibrillation,
stroke, congestive heart failure, and mortality, especially in
elderly people (21). Even in young and healthy subjects
(n = 2,804, mean age 59.2 years), the LA diameter is a strong
and independent predictor of the development of cardio-
vascular events during follow-up (22). The LA size
demonstrates a greater predictive value compared with
LV diastolic function measurements and filling pressures,
which are substantially influenced by hemodynamics (6,23).
Similar to the association between the finger-stick glucose
level and HbA1c value in diabetic patients, LV filling
pressures, as measured by conventional and tissue Doppler
imaging, are appropriate for monitoring short-term hemo-
dynamic status, but LA measurements are more relevant for
determining the average effect of the left ventricular filling
pressure over time (24). Although the LA diameter is an
easily quantifiable parameter by using M-mode, its accuracy
in reflecting LA size is controversial due to the asymmetric
structure of the LA (4,5). Currently, the LA volume
measured using the modified Simpson technique from the
apical four-chamber view indexed to the body surface area
(LAVI) is the preferred method for LA quantification (5). A
LAVI$32 mL/m2 determines abnormal diastolic function
with 100% specificity and 67% sensitivity (25). In our study,
the LA diameter and LAVI were correlated with each other
(p,0.05). We did not observe an association between age,
gender, BMI, and atrial measurements. The LAVI was
increased in hypertensive patients (29.2 vs. 24.7 mL/m2,
p= 0.01). Impaired LV diastolic function in essential hyper-
tension may account for the higher LAVI in these patients.
In patients with acute STEMI, there is an inverse
relationship between LV and LA functions unless LA is
affected from an ischemic event (26). LV function is
reduced, while an increase in LA function is observed.
While the contribution of LA to LV stroke volume is 20% in
normal individuals, it increases to 35% in STEMI. Thus,
atrial contraction greatly contributes to LV stroke volume
and filling pressure in STEMI sufferers irrespective of
impairment in ventricular function. A few studies have
examined atrial changes in patients with acute STEMI
(6,22,27,28). The presence of heart failure at admission,
fibrinolytic therapy, moderate to severe mitral regurgitation,
LV systolic dysfunction, and poor myocardial perfusion
following revascularization were associated with an
enlarged LA. We observed no association between MI
location (anterior, inferior), the IRA (LAD, Cx, RCA), the
method of reperfusion (primary PCI, fibrinolytics), and
atrial dimensions. We believe that early successful revascu-
larization of our patients, often with primary PCI, and the
spontaneous recanalization observed in most of the non-
intervened patients contributed to this finding. Again,
vessel score, which reflects the extent of CAD, was not
associated with atrial dimensions. The Gensini score, used
Figure 1 - Scatter plot of the patients’ plasma NT-proANP levels (nmol/L) against the LAVI values (mL/m2) (r = 0.28, p=0.01).
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for the assessment of the severity of CAD, was correlated
with left atrial diameter and volume (p,0.01). LV diastolic
dysfunction associated with chronic myocardial ischemia
may have resulted in increased LA dimensions. There was a
positive correlation between the LAVI and the E/Em ratio, a
sensitive marker of diastolic dysfunction (p,0.05).
Essentially, myocardial ischemia stimulates ANP release
by increasing both LV end-diastolic pressure and wall
tension (29). The correlation observed between the max-
imum CK-MB level (an index of infarction size) and ANP
level during the early phase of STEMI (the first 6 hours) led
us to hypothesize that ANP release is essentially an
indicator of the severity of the infarction and that ANP is
released from ischemic cardiac tissues (30). However, no
association was found between ANP level and infarct
location, the number of vessels involved, or whether
reperfusion could be achieved. The plasma ANP level
measured on the first day of MI was correlated with the
mean right atrial pressure, pulmonary artery pressure, and
PCWP recorded during right cardiac catheterization, but
they did not change in patients without a decreased cardiac
index (31). Elevated ANP levels during STEMI is associated
with the development of heart failure and increased cardiac
mortality (10,31,32). In our study, NT-proANP levels were
nearly 2.5 times higher in patients than controls. ANP was
also elevated in elderly, hypertensive, and diabetic patients.
Our findings do not differ from those of previous studies
that demonstrated elevated natriuretic peptide in subjects
with essential hypertension, especially when left ventricular
hypertrophy and DM are present (33,34). We found that NT-
proANP was more likely to correlate with the peak level of
troponin I, a more sensitive marker, than with CK-MB. We
did not observe any association between the location of MI
(e.g., anterior or inferior), IRA or the number of vessels
involved (as quantified by the vessel score), and NT-
proANP level. The observed correlation between the
Gensini score, which is an indicator of CAD severity, and
the NT-proANP level may have resulted from lower EF
values in patients with higher Gensini scores. NT-proANP
was also higher in patients who underwent primary PCI
compared with patients administered fibrinolytic therapy
(p= 0.03). PTCA-induced myocardial ischemia may have
been the cause of this elevation. In patients undergoing
primary PCI, the time elapsed from the onset of pain to
revascularization was correlated with ANP level (p= 0.02). It
is possible that the size of myocardial damage and the NT-
proANP level increased due to delays in performing the
procedure.
When the previous studies that examined the associations
between ANP level and echocardiographic parameters in
patients with STEMI were revised, the NT-proANP level
obtained during hospitalization was found to correlate with
LVESD and EF in patients receiving thrombolytic therapy
(10). In a more recent study, Elmas et al. evaluated the
plasma levels of midregional pro–A-type natriuretic peptide
(MR-proANP), a newly developed assay for ANP quantifi-
cation, and NT-proBNP in 102 patients with a history of
STEMI (35). They demonstrated that MR-proANP was the
strongest predictor of LVEF, even superior to NT-proBNP.
However, Nagaya et al. measured post-infarction natriuretic
peptide without taking into account the success of revascu-
larization or the therapy administered, and they failed to
show a relationship between plasma ANP level and changes
in LV size and function (36). Similarly, we did not find an
association between NT-proANP level and LV diameter or
EF in our study. This finding could be explained by the
preserved LV function in most patients (mean
LVEF = 49.4¡7.1%) due to timely and successful reperfusion.
LAVI was the only echocardiographic variable that corre-
lated with NT-proANP level (r = 0.283, p= 0.01). Furthermore,
it was independently associated with NT-proANP level. The
results of our study are consistent with the results of the
ROMICAT Trial, which reported an independent association
between MR-proANP concentration and LA enlargement but
not between MR-proANP and LV measures in adult patients
without heart failure (37).
Based on this association between NT-proANP and LAVI,
we may suggest that the major source of ANP after an acute
STEMI is the left atrium. The clinical importance of this
result is that measuring LAVI as part of the routine
echocardiographic examination in patients who have
suffered an acute STEMI could provide valuable clinical
and prognostic data. Although the long-term prognostic
significance of increased LAVI in STEMI is well known,
elevated NT-proANP, which is also a marker of adverse
cardiovascular outcomes, may help explain the unfavorable
results associated with LA dilation.
Study limitations
This study had several limitations, the most significant of
which was the relatively small sample size. LA size could
have been estimated with newer techniques, such as real-
time three-dimensional echocardiography, but we chose to
use 2D echocardiography due to limited experience with the
former technique in these patients. The other limitation was
the absence of LV pressure data. The LA, LV filling, and
end-diastolic pressures could have been measured inva-
sively, but we evaluated the Doppler parameters of diastolic
function instead. These measures accurately predict LV
pressures (6). Additionally, the contribution of medical
therapy to the changes in LA size and NT-proANP level was
not considered. Another potential limitation of the study is
that we did not assess BNP. Lim et al. reported the value of
BNP together with echocardiographic measurements in
acute STEMI patients; therefore, we did not measure serum
BNP (38). The current study was not designed to investigate
mortality or major adverse cardiac events but instead
focused on the possible association between NT-proANP
level and LA size in patients with STEMI.
Increased left atrial volume and ANP, a major peptide
released from atria, are strong predictors of post-MI
survival. Whereas ANP measurement is expensive and
cumbersome in clinical practice, the LAVI may be easily
quantified during routine echocardiographic examination.
In this study, we demonstrated that plasma NT-proANP
increased due to enlargement of the LA in STEMI patients.
The results of this study reveal a strong association between
LAVI and NT-proANP. It may be beneficial to assess the
LAVI, which is simple and convenient, instead of NT-
proANP in patients with acute STEMI.
& AUTHOR CONTRIBUTIONS
Bacaksiz A participated in the study design, carried out the echocardio-
graphic examinations, contributed to the writing of the manuscript, and
drafted the manuscript. Vatankulu MA participated in the study design,
carried out the echocardiographic examinations, and contributed to the
writing of the manuscript. Kayrak M conceived the study and performed
the statistical analysis. Telli HH contributed to the study design, reviewed
LAVI and NT-proANP in AMI
Bacaksiz A et al.
CLINICS 2013;68(7):997-1003
1002
the manuscript, and contributed to the oversight and organization. Ayhan
SS participated in the study design and in the revision of the manuscript.
Sonmez O participated in the study design and contributed to the writing
of the manuscript. Alp A and Buyukbas S participated in the study design
and performed the biochemical measurements. All authors approved the
final version of the manuscript.
& REFERENCES
1. Welch TD, Yang EH, Reeder GS, Gersh BJ. Modern management of acute
myocardial infarction. Curr Probl Cardiol. 2012;37(7):237-310, http://dx.
doi.org/10.1016/j.cpcardiol.2012.03.002.
2. Souza LP, Campos O, Peres CA, Machado CV, Carvalho AC.
Echocardiographic predictors of early in-hospital heart failure during
first ST-elevation acute myocardial infarction: does myocardial perfor-
mance index and left atrial volume improve diagnosis over conventional
parameters of left ventricular function? Cardiovasc Ultrasound.
2011;9:17, http://dx.doi.org/10.1186/1476-7120-9-17.
3. Choong CY, Hermann HC, Weymann AE, Fifer MA. Preload depen-
dence of Doppler-derived indexes of left ventricular diastolic function in
humans. J Am Coll Cardiol. 1987;10(4):800-8, http://dx.doi.org/10.1016/
S0735-1097(87)80273-5.
4. Patel DA, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical implications
of left atrial enlargement: a review. Ochsner J. 2009;9(4):191-6.
5. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka
PA, et al. Recommendations for chamber quantification: a report from
the American Society of Echocardiography’s Guidelines and Standards
Committee and the Chamber Quantification Writing Group, developed
in conjunction with the European Association of Echocardiography, a
branch of the European Society of Cardiology. J Am Soc Echocardiogr.
2005;18(12):1440-63, http://dx.doi.org/10.1016/j.echo.2005.10.005.
6. Møller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, et al. Left
atrial volume: a powerful predictor of survival after myocardial
infarction. Circulation. 2003;107(17):2207-12, http://dx.doi.org/10.1161/
01.CIR.0000066318.21784.43.
7. Hoffmann U, Brueckmann M, Bertsch T, Wiessner M, Liebetrau C, Lang S,
et al. Increased plasma levels of NT-proANP and NT-proBNP as markers
of cardiac dysfunction in septic patients. Clin Lab. 2005;51(7-8):373-9.
8. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as
an endocrine organ: physiological role and clinical utility of cardiac
natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011;301(1):H12-
20, http://dx.doi.org/10.1152/ajpheart.00226.2011.
9. Bartkowiak R, Wozakowska-Kapłon B, Janiszewska G. Plasma NT-
proANP in patients with persistent atrial fibrillation who underwent
successful cardioversion. Kardiol Pol. 2010;68(1):48-54.
10. Magga J, Puhakka M, Hietakorpi S, Punnonen K, Uusimaa P, Risteli J,
et al. Atrial natriuretic peptide, B-type natriuretic peptide, and serum
collagen markers after acute myocardial infarction. J Appl Physiol.
2004;96(4):1306-11, http://dx.doi.org/10.1152/japplphysiol.00557.2003.
11. Katayama T, Nakashima H, Furudono S, Honda Y, Suzuki S, Yano K.
Evaluation of neurohumoral activation (adrenomedullin, BNP, catechola-
mines, etc.) in patients with acute myocardial infarction. Intern Med.
2004;43(11):1015-22, http://dx.doi.org/10.2169/internalmedicine.43.1015.
12. Nakamura M, Arakawa N, Yoshida H, Funakoshi T, Chiba M, Makita S,
et al. Prognostic Implications of Plasma Levels of Atrial Natriuretic
Factor in Patients with Acute Myocardial Infarction. Intern Med.
1993;32(2):112-5, http://dx.doi.org/10.2169/internalmedicine.32.112.
13. Svanegaard J, Johansen JB, Klitgaard NA, Thayssen P, Haghfelt T.
Correlation between serial changes in left-sided heart chambers and
atrial natriuretic peptide and N-terminal pro atrial natriuretic peptide
after a first myocardial infarction. An echocardiographic study. Scand
Cardiovasc J. 1999;33(6):355-61.
14. Taylor J. Third universal definition of myocardial infarction. Eur Heart J.
2012;33(20):2506-7.
15. Schiller NB, Acquatella H, Ports TA, Drew D, Goerke J, Ringertz H, et al.
Left ventricular volume from paired biplane two-dimensional echocar-
diography. Circulation. 1979;60(3):547-55, http://dx.doi.org/10.1161/01.
CIR.60.3.547.
16. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring
coronary angiograms to reflect extent of coronary atherosclerosis and
improve correlation with major risk factors. Am Heart J.
1990;119(6):1262-7, http://dx.doi.org/10.1016/S0002-8703(05)80173-5.
17. Gensini GG. A more meaningful scoring system for determining the
severity of coronary heart disease. Am J Cardiol. 1983;51(3):606, http://
dx.doi.org/10.1016/S0002-9149(83)80105-2.
18. Rossi A, Cicoira M, Zanolla L, Sandrini R, Golia G, Zardini P, et al.
Determinants and prognostic value of left atrial volume in patients with
dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(8):1425-30, http://
dx.doi.org/10.1016/S0735-1097(02)02305-7.
19. Rossi A, Tomaino M, Golia G, Sentini F, Pentiricci S, Marino P, et al.
Usefulness of left atrial size in predicting postoperative symptomatic
improvement in patients with aortic stenosis. Am J Cardiol.
2000;86(5):567-70, http://dx.doi.org/10.1016/S0002-9149(00)01019-5.
20. Jikuhara T, Sumimoto T, Tarumi N, Yuasa F, Hattori T, Sugiura T, et al.
Left atrial function as a reliable predictor of exercise capacity in patients
with recent myocardial infarction. Chest. 1997;111(4):922-8, http://dx.
doi.org/10.1378/chest.111.4.922.
21. Takemoto Y, Barnes ME, Seward JB, Lester SJ, Appleton CA, Gersh BJ,
et al. Usefulness of left atrial volume in predicting first congestive heart
failure in patients . or = 65 years of age with well-preserved left
ventricular systolic function. Am J Cardiol. 2005;96(6):832-6, http://dx.
doi.org/10.1016/j.amjcard.2005.05.031.
22. Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, et al. Left atrial
diameter as an independent predictor of first clinical cardiovascular events
in middle-aged and elderly adults: The Strong Heart Study (SHS). Am
Heart J. 2006;151(2):412-8, http://dx.doi.org/10.1016/j.ahj.2005.04.031.
23. Beinart R, Boyko V, Schwammenthal E, Kuperstein R, Sagie A, Hod H,
et al. Long-term prognostic significance of left atrial volume in acute
myocardial infarction. J Am Coll Cardiol. 2004;44(2):327-34, http://dx.
doi.org/10.1016/j.jacc.2004.03.062.
24. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction
and cardiovascular disease risk. J Am Coll Cardiol. 2003;42(7):1206-7,
http://dx.doi.org/10.1016/S0735-1097(03)00956-2.
25. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left Atrial
Volume as a Morphophysiologic Expression of Left Ventricular Diastolic
Dysfunction and Relation to Cardiovascular Risk Burden. Am J Cardiol.
2002;90(12):1284-9, http://dx.doi.org/10.1016/S0002-9149(02)02864-3.
26. Sigwart U, Grbic M, Goy J, Kappenberger L. Left atrial function in acute
transient left ventricular ischemia produced during percutaneous
transluminal coronary angioplasty of the left anterior descending
coronary artery. Am J Cardiol. 1990;65(5):282-6, http://dx.doi.org/10.
1016/0002-9149(90)90288-C.
27. Ahn SG, Shin JH, Koh BR, Choi JH, Kang SJ, Choi BJ, et al. Impact of
myocardial perfusion on left atrial remodeling following primary
angioplasty for acute myocardial infarction. Coron Artery Dis.
2006;17(7):597-603, http://dx.doi.org/10.1097/01.mca.0000236281.74361.
d4.
28. Feinberg MS, Boyko V, Leor J, Kuperstein R, Sagie A, Hod H, et al.
Differential value of left atrial systolic and diastolic volumes as
independent predictors of congestive heart failure or early death in
acute myocardial infarction. Heart. 2006;92(3):397-8.
29. Bergeron S, Møller JE, Bailey KR, Chen HH, Burnett JC, Pellikka PA.
Exertional Changes in Circulating Cardiac Natriuretic Peptides in
Patients with Suggested Coronary Artery Disease. J Am Soc
Echocardiogr. 2006;19(6):772-6, http://dx.doi.org/10.1016/j.echo.2006.
01.010.
30. Tan AC, van Loenhout TT, Lamfers EJ, Hooghoudt TE, Kloppenborg
PW, Benraad TJ. Atrial natriuretic peptide after myocardial infarction.
Am Heart J. 1989;118(3):490-4, http://dx.doi.org/10.1016/0002-8703(89)
90262-7.
31. Hara H, Ogihara T, Nakamaru M, Rakugi H,Tateyama H. Changes in the
levels of plasma atrial natriuretic peptide, hemodynamic measurements,
and the levels of vasoactive hormones during the clinical course of
congestive heart failure. Clin Cardiol. 1988;11(11):743-7, http://dx.doi.
org/10.1002/clc.4960111104.
32. Hall C, Rouleau JL, Moye` L, de Champlain J, Bichet D, Klein M, Sussex B,
et al. N-Terminal Proatrial Natriuretic Factor. An Independent Predictor
of Long-term Prognosis After Myocardial Infarction. Circulation.
1994;89(5):1934-42.
33. Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E.
Defective regulation and action of atrial natriuretic peptide in type 2
diabetes. Horm Metab Res. 2002;34(5):265-70, http://dx.doi.org/10.
1055/s-2002-32141.
34. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y,
et al. Relationship between left ventricular geometry and natriuretic
peptide levels in essential hypertension. Hypertension. 1996;28(1):22-30,
http://dx.doi.org/10.1161/01.HYP.28.1.22.
35. Elmas E, Brueckmann M, Lang S, Ka¨lsch T, Haghi D, Sueselbeck T, et al.
Midregional pro-atrial natriuretic peptide is a useful indicator for the
detection of impaired left ventricular function in patients with coronary
artery disease. Int J Cardiol. 2008;128(2):244-9.
36. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, et al.
Plasma brain natriuretic peptide is a biochemical marker for the
prediction of progressive ventricular remodeling after acute myocardial
infarction. Am Heart J. 1998;135(1):21-8, http://dx.doi.org/10.1016/
S0002-8703(98)70338-2.
37. Truong QA, Siegel E, Karakas M, Januzzi JL Jr, Bamberg F, Mahabadi
AA, et al. Relation of natriuretic peptides and midregional proadreno-
medullin to cardiac chamber volumes by computed tomography in
patients without heart failure: from the ROMICAT Trial. Clin Chem.
2010;56(4):651-60, http://dx.doi.org/10.1373/clinchem.2009.138586.
38. Lim TK, Hayat SA, Gaze D, Celik E, Collinson P, Senior R. Independent
value of echocardiography and N-terminal pro-natriuretic Peptide for
the prediction of major outcomes in patients with suspected heart failure.
Am J Cardiol. 2007;100(5):870-5, http://dx.doi.org/10.1016/j.amjcard.
2007.04.027.
CLINICS 2013;68(7):997-1003 LAVI and NT-proANP in AMI
Bacaksiz A et al.
1003
